Placebo-controlled study of the D4/5-HT(2A) antagonist fananserin in the treatment of schizophrenia

American Journal of Psychiatry

Volumn 156, Issue 3, 1999, Pages 419-425

  Truffinet, Philippe ^a   Tamminga, Carol A ^b   Fabre, Louis F ^b   Meltzer, Herbert Y ^b   Rivière, Marie Emmanuelle ^b   Papillon Downey, Catherine ^b  

^a SANOFI   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FANANSERIN; SEROTONIN 2 ANTAGONIST;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM;

ADOLESCENT; ADULT; CYCLIC S-OXIDES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALIZATION; HUMANS; MALE; NAPHTHALENES; PATIENT DROPOUTS; PLACEBO EFFECT; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 0033052763     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kane JM, Freeman HL: Towards more effective antipsychotic treatment. Br J Psychiatry 1994; 165(suppl 25):22-31
2. Meltzer HY: The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991; 17:263-287
3. Gerlach J, Peacock L: New antipsychotics: the present status. Int Clin Psychopharmacol 1995; 10(suppl 3):39-48
4. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350:610-614
5. Seeman P, Van Tol HHM: Dopamine receptor pharmacology. Trends Pharmacol Sci 1994; 15:264-270
6. 1 values. J Pharmacol Exp Ther 1989; 251:283-246
7. 4 receptor. Eur J Pharmacol 1996; 314:229-233
8. 2 receptor antagonist. Br J Pharmacol 1992; 105:27-36
9. 2 antagonists endowed with anxiolytic properties in rodents? Neurosci Lett 1991; 128: 4-8
10. Kane JM, Schooler NR, Marder SR, Simpson GM, Casey DE: Methods for clinical evaluation of pharmacologic treatments of schizophrenia, in Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. Edited by Prien RF, Robinson DS. New York, Raven Press, 1994, pp 345-372
11. Addington D: The use of placebos in clinical trials for acute schizophrenia. Can J Psychiatry 1995; 40:171-176
12. Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res 1988; 23:99-110
13. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976, pp 217-222
14. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
15. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
16. SAS/STAT User's Guide, version 6, 4th ed, vols 1, 2. Cary, NC, SAS Institute, 1990
17. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB: Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154:782-791
18. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111-123
19. Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia versus haloperidol. Br J Psychiatry 1995; 166:712-726
20. 4 receptors in the action and development of antipsychotic agents. Drugs 1996; 51:7-11
21. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry 1997; 54:567-572
22. Kapur S, Remington G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153: 466-476